ACRUX LIMITED - Announcements

0.00%

1.8¢

Market Cap $7.366M

Healthcare Drug Manufacturers - Specialty & Generic

Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is... Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

ACR	Acrux provides half-year update	PRICE SENSITIVE	18/02/13	62.78KB	Share
ACR	Half Yearly Report and Accounts	PRICE SENSITIVE	18/02/13	314.58KB	Share
ACR	Ceasing to be a substantial holder		14/02/13	84.33KB	Share
ACR +AMP	Becoming a substantial holder from AMP		13/02/13	442.47KB	Share
ACR	Allowance of underarm administration patent in United States	PRICE SENSITIVE	12/02/13	20KB	Share
ACR	Change in substantial holding		08/02/13	119.46KB	Share
ACR	Ceasing to be a substantial holder		20/12/12	82.48KB	Share
ACR	Becoming a substantial holder		19/12/12	3.25MB	Share
ACR	Becoming a substantial holder		18/12/12	83.06KB	Share
ACR	Change of Director's Interest Notice		27/11/12	13.39KB	Share
ACR	2012 AGM Results of Meeting		22/11/12	55.4KB	Share
ACR	2012 AGM Presentation	PRICE SENSITIVE	22/11/12	203.11KB	Share
ACR	2012 AGM Chairman's Address		22/11/12	82.73KB	Share
ACR	2012 Annual Report		19/10/12	1.1MB	Share
ACR	Notice of Annual General Meeting/Proxy Form		19/10/12	654.86KB	Share
ACR	Change in substantial holding		12/10/12	112.98KB	Share
ACR	Change of Director's Interest Notice		02/10/12	11.6KB	Share
ACR	Becoming a substantial holder		17/09/12	435.39KB	Share
ACR +AMP	Ceasing to be a substantial holder from AMP		13/09/12	342.3KB	Share
ACR	Change of Director's Interest Notice		13/09/12	13.38KB	Share
ACR +AMP	Change in substantial holding from AMP		07/09/12	395.11KB	Share
ACR	Ceasing to be a substantial holder		29/08/12	836.44KB	Share
ACR	Dividend, June 2012 results and Axiron update	PRICE SENSITIVE	23/08/12	31.39KB	Share
ACR	Investor presentation, 23 August 2012		23/08/12	1.18MB	Share
ACR	Appendix 4E and Financial Report for 30 June 2012	PRICE SENSITIVE	23/08/12	1.69MB	Share
ACR +AMP	Change in substantial holding from AMP		17/08/12	399.64KB	Share
ACR	Change in substantial holding		08/08/12	100.55KB	Share
ACR	Final Director's Interest Notice		02/07/12	64.22KB	Share
ACR	Recuvyra approved by FDA	PRICE SENSITIVE	26/06/12	16.55KB	Share
ACR	Patent application update	PRICE SENSITIVE	21/06/12	19.77KB	Share
ACR	Axiron Marketing Authorisation Granted in Australia	PRICE SENSITIVE	25/05/12	21.48KB	Share
ACR	Becoming a substantial holder		23/05/12	131.41KB	Share
ACR +AMP	Change in substantial holding from AMP		15/05/12	365.82KB	Share
ACR	Change in substantial holding		14/05/12	92.31KB	Share
ACR	Change in substantial holding		10/05/12	92.55KB	Share
ACR +AMP	Change in substantial holding from AMP		10/05/12	357.02KB	Share
ACR +AMP	Becoming a substantial holder from AMP		08/05/12	213.48KB	Share
ACR	Change in substantial holding		07/05/12	90.84KB	Share
ACR	Becoming a substantial holder		07/05/12	287.75KB	Share
ACR	Investor presentation, 7 May 2012		07/05/12	1.15MB	Share
ACR	Change in substantial holding		02/05/12	90.76KB	Share
ACR	Acrux announces further board change		01/05/12	21.71KB	Share
ACR	Initial Director's Interest Notice		01/05/12	67.43KB	Share
ACR	Final Director's Interest Notice		01/05/12	64.02KB	Share
ACR	Change of Director's Interest Notice		01/05/12	11.66KB	Share
ACR	Change in substantial holding		26/04/12	93.93KB	Share
ACR	Axiron market update	PRICE SENSITIVE	26/04/12	22.06KB	Share
ACR	Axiron marketing authorisation granted in Canada	PRICE SENSITIVE	12/04/12	19.93KB	Share
ACR	Initial Director's Interest Notice		05/04/12	65.92KB	Share
ACR	Change of Director's Interest Notice		02/04/12	10.63KB	Share
ACR	Change in substantial holding		26/03/12	91.93KB	Share
ACR	Acrux reports half-year profit of $5.1 million		22/02/12	33.21KB	Share
ACR	Acrux announces board changes	PRICE SENSITIVE	22/02/12	40.24KB	Share
ACR	Investor presentation, 22 February 2012		22/02/12	1.26MB	Share
ACR	Half Yearly Report and Accounts	PRICE SENSITIVE	22/02/12	200.82KB	Share
ACR	Notice of Allowance in USA for Axiron applicator patent	PRICE SENSITIVE	31/01/12	20.23KB	Share
ACR	Marketing approval granted for Ellavie in Switzerland	PRICE SENSITIVE	30/01/12	21.77KB	Share
ACR	Lilly comments on Axiron at JP Morgan Healthcare Conference		13/01/12	20.04KB	Share
ACR	Orion manufacturing facility update	PRICE SENSITIVE	01/12/11	19.89KB	Share
ACR	Orion manufacturing facility, Finland	PRICE SENSITIVE	24/11/11	19.89KB	Share
ACR	2011 AGM Results of Meeting		23/11/11	55.36KB	Share
ACR	2011 AGM CEO Presentation		23/11/11	1.33MB	Share
ACR	2011 AGM Chairman's Address		23/11/11	14.85KB	Share
ACR	Change of Director's Interest Notice		04/11/11	70.74KB	Share
ACR	2026 patent for Axiron granted by Australian patent office	PRICE SENSITIVE	03/11/11	21.74KB	Share
ACR	2011 AGM Notice and Proxy Form		21/10/11	207.02KB	Share
ACR	2011 Annual Report		21/10/11	1.49MB	Share
ACR	Marketing authorisation for Recuvyra granted in Europe	PRICE SENSITIVE	13/10/11	17.32KB	Share
ACR	Market Update		28/09/11	20.28KB	Share
ACR +ALD ALK API ASZ BKY BSL CCP CNP CPB CUS DCG K2P FML ETM GMG HIL HUN IDL IFN ILU MCP MCR MEO MTU NDO OST PPT SRS IMM QUB RHG SFH SPL SSN STB TGA TGS ZSP	SandP Indices Announces September Quarterly Rebalance	PRICE SENSITIVE	09/09/11	62.33KB	Share
ACR	Change in substantial holding		08/09/11	91.95KB	Share
ACR +HIL IFN QUB ZSP	SandP Indices Announces September SP/ASX 200 Rebalance		02/09/11	94.2KB	Share
ACR	Change of Director's Interest Notice		31/08/11	70.42KB	Share
ACR	Final Director's Interest Notice		31/08/11	65.12KB	Share
ACR	Acrux founder Barrie Finnin retires from the board		31/08/11	20.22KB	Share
ACR	Acrux not required to file quarterly cash flow reports		31/08/11	33.34KB	Share
ACR	Eli Lilly Report to Acrux Investment Community		23/08/11	2.3MB	Share
ACR	2010/11 Financial Results		23/08/11	96.07KB	Share
ACR	Acrux Reports Full Year Profit of $57 Million		23/08/11	45.93KB	Share
ACR	Appendix 4E and Financial Report for the year ended 30 June	PRICE SENSITIVE	23/08/11	3.55MB	Share
ACR	Change in substantial holding		02/08/11	88.44KB	Share
ACR	Appendix 4C - Quarterly Cash Flow Report	PRICE SENSITIVE	29/07/11	90.03KB	Share
ACR	Change in substantial holding		18/07/11	88.99KB	Share
ACR	Eli Lilly provides feedback on initial uptake of Axiron	PRICE SENSITIVE	01/07/11	517.82KB	Share
ACR	Acrux receives marketing approval for Ellavie in Sweden	PRICE SENSITIVE	27/05/11	125.04KB	Share
ACR	Appendix 3B		12/05/11	166.81KB	Share
ACR	Positive European opinion for first animal health product	PRICE SENSITIVE	10/05/11	98.91KB	Share
ACR	Appendix 4C - Quarterly Cash Flow Report	PRICE SENSITIVE	29/04/11	89.96KB	Share
ACR	Appendix 3B		07/04/11	167.78KB	Share
ACR	Axiron Launched by Eli Lilly in the United States	PRICE SENSITIVE	31/03/11	52.55KB	Share
ACR	Acrux Declares First Dividend of 60 cents per share	PRICE SENSITIVE	24/03/11	46.13KB	Share
ACR	Appendix 3B		16/03/11	167.39KB	Share
ACR	Acrux Files Half Year Results		24/02/11	49.74KB	Share
ACR	Half Year Accounts and Appendix 4D	PRICE SENSITIVE	24/02/11	272.94KB	Share
ACR	Appendix 3B		15/02/11	167.41KB	Share
ACR	Ceasing to be a substantial holder		04/02/11	60.33KB	Share
ACR	Appendix 4C - Quarterly Cash Flow Report	PRICE SENSITIVE	31/01/11	89.75KB	Share
ACR	Appendix 3B		21/01/11	167.41KB	Share
ACR	Regulatory update on animal health product		13/01/11	20.07KB	Share
ACR	Share Trading Policy		24/12/10	24.62KB	Share

ACR Acrux provides half-year update
18/02/13	PRICE SENSITIVE	62.78KB	Share
ACR Half Yearly Report and Accounts
18/02/13	PRICE SENSITIVE	314.58KB	Share
ACR Ceasing to be a substantial holder
14/02/13		84.33KB	Share
ACR +AMP Becoming a substantial holder from AMP
13/02/13		442.47KB	Share
ACR Allowance of underarm administration patent in United States
12/02/13	PRICE SENSITIVE	20KB	Share
ACR Change in substantial holding
08/02/13		119.46KB	Share
ACR Ceasing to be a substantial holder
20/12/12		82.48KB	Share
ACR Becoming a substantial holder
19/12/12		3.25MB	Share
ACR Becoming a substantial holder
18/12/12		83.06KB	Share
ACR Change of Director's Interest Notice
27/11/12		13.39KB	Share
ACR 2012 AGM Results of Meeting
22/11/12		55.4KB	Share
ACR 2012 AGM Presentation
22/11/12	PRICE SENSITIVE	203.11KB	Share
ACR 2012 AGM Chairman's Address
22/11/12		82.73KB	Share
ACR 2012 Annual Report
19/10/12		1.1MB	Share
ACR Notice of Annual General Meeting/Proxy Form
19/10/12		654.86KB	Share
ACR Change in substantial holding
12/10/12		112.98KB	Share
ACR Change of Director's Interest Notice
02/10/12		11.6KB	Share
ACR Becoming a substantial holder
17/09/12		435.39KB	Share
ACR +AMP Ceasing to be a substantial holder from AMP
13/09/12		342.3KB	Share
ACR Change of Director's Interest Notice
13/09/12		13.38KB	Share
ACR +AMP Change in substantial holding from AMP
07/09/12		395.11KB	Share
ACR Ceasing to be a substantial holder
29/08/12		836.44KB	Share
ACR Dividend, June 2012 results and Axiron update
23/08/12	PRICE SENSITIVE	31.39KB	Share
ACR Investor presentation, 23 August 2012
23/08/12		1.18MB	Share
ACR Appendix 4E and Financial Report for 30 June 2012
23/08/12	PRICE SENSITIVE	1.69MB	Share
ACR +AMP Change in substantial holding from AMP
17/08/12		399.64KB	Share
ACR Change in substantial holding
08/08/12		100.55KB	Share
ACR Final Director's Interest Notice
02/07/12		64.22KB	Share
ACR Recuvyra approved by FDA
26/06/12	PRICE SENSITIVE	16.55KB	Share
ACR Patent application update
21/06/12	PRICE SENSITIVE	19.77KB	Share
ACR Axiron Marketing Authorisation Granted in Australia
25/05/12	PRICE SENSITIVE	21.48KB	Share
ACR Becoming a substantial holder
23/05/12		131.41KB	Share
ACR +AMP Change in substantial holding from AMP
15/05/12		365.82KB	Share
ACR Change in substantial holding
14/05/12		92.31KB	Share
ACR Change in substantial holding
10/05/12		92.55KB	Share
ACR +AMP Change in substantial holding from AMP
10/05/12		357.02KB	Share
ACR +AMP Becoming a substantial holder from AMP
08/05/12		213.48KB	Share
ACR Change in substantial holding
07/05/12		90.84KB	Share
ACR Becoming a substantial holder
07/05/12		287.75KB	Share
ACR Investor presentation, 7 May 2012
07/05/12		1.15MB	Share
ACR Change in substantial holding
02/05/12		90.76KB	Share
ACR Acrux announces further board change
01/05/12		21.71KB	Share
ACR Initial Director's Interest Notice
01/05/12		67.43KB	Share
ACR Final Director's Interest Notice
01/05/12		64.02KB	Share
ACR Change of Director's Interest Notice
01/05/12		11.66KB	Share
ACR Change in substantial holding
26/04/12		93.93KB	Share
ACR Axiron market update
26/04/12	PRICE SENSITIVE	22.06KB	Share
ACR Axiron marketing authorisation granted in Canada
12/04/12	PRICE SENSITIVE	19.93KB	Share
ACR Initial Director's Interest Notice
05/04/12		65.92KB	Share
ACR Change of Director's Interest Notice
02/04/12		10.63KB	Share
ACR Change in substantial holding
26/03/12		91.93KB	Share
ACR Acrux reports half-year profit of $5.1 million
22/02/12		33.21KB	Share
ACR Acrux announces board changes
22/02/12	PRICE SENSITIVE	40.24KB	Share
ACR Investor presentation, 22 February 2012
22/02/12		1.26MB	Share
ACR Half Yearly Report and Accounts
22/02/12	PRICE SENSITIVE	200.82KB	Share
ACR Notice of Allowance in USA for Axiron applicator patent
31/01/12	PRICE SENSITIVE	20.23KB	Share
ACR Marketing approval granted for Ellavie in Switzerland
30/01/12	PRICE SENSITIVE	21.77KB	Share
ACR Lilly comments on Axiron at JP Morgan Healthcare Conference
13/01/12		20.04KB	Share
ACR Orion manufacturing facility update
01/12/11	PRICE SENSITIVE	19.89KB	Share
ACR Orion manufacturing facility, Finland
24/11/11	PRICE SENSITIVE	19.89KB	Share
ACR 2011 AGM Results of Meeting
23/11/11		55.36KB	Share
ACR 2011 AGM CEO Presentation
23/11/11		1.33MB	Share
ACR 2011 AGM Chairman's Address
23/11/11		14.85KB	Share
ACR Change of Director's Interest Notice
04/11/11		70.74KB	Share
ACR 2026 patent for Axiron granted by Australian patent office
03/11/11	PRICE SENSITIVE	21.74KB	Share
ACR 2011 AGM Notice and Proxy Form
21/10/11		207.02KB	Share
ACR 2011 Annual Report
21/10/11		1.49MB	Share
ACR Marketing authorisation for Recuvyra granted in Europe
13/10/11	PRICE SENSITIVE	17.32KB	Share
ACR Market Update
28/09/11		20.28KB	Share
ACR +ALD ALK API ASZ BKY BSL CCP CNP CPB CUS DCG K2P FML ETM GMG HIL HUN IDL IFN ILU MCP MCR MEO MTU NDO OST PPT SRS IMM QUB RHG SFH SPL SSN STB TGA TGS ZSPSandP Indices Announces September Quarterly Rebalance
09/09/11	PRICE SENSITIVE	62.33KB	Share
ACR Change in substantial holding
08/09/11		91.95KB	Share
ACR +HIL IFN QUB ZSPSandP Indices Announces September SP/ASX 200 Rebalance
02/09/11		94.2KB	Share
ACR Change of Director's Interest Notice
31/08/11		70.42KB	Share
ACR Final Director's Interest Notice
31/08/11		65.12KB	Share
ACR Acrux founder Barrie Finnin retires from the board
31/08/11		20.22KB	Share
ACR Acrux not required to file quarterly cash flow reports
31/08/11		33.34KB	Share
ACR Eli Lilly Report to Acrux Investment Community
23/08/11		2.3MB	Share
ACR 2010/11 Financial Results
23/08/11		96.07KB	Share
ACR Acrux Reports Full Year Profit of $57 Million
23/08/11		45.93KB	Share
ACR Appendix 4E and Financial Report for the year ended 30 June
23/08/11	PRICE SENSITIVE	3.55MB	Share
ACR Change in substantial holding
02/08/11		88.44KB	Share
ACR Appendix 4C - Quarterly Cash Flow Report
29/07/11	PRICE SENSITIVE	90.03KB	Share
ACR Change in substantial holding
18/07/11		88.99KB	Share
ACR Eli Lilly provides feedback on initial uptake of Axiron
01/07/11	PRICE SENSITIVE	517.82KB	Share
ACR Acrux receives marketing approval for Ellavie in Sweden
27/05/11	PRICE SENSITIVE	125.04KB	Share
ACR Appendix 3B
12/05/11		166.81KB	Share
ACR Positive European opinion for first animal health product
10/05/11	PRICE SENSITIVE	98.91KB	Share
ACR Appendix 4C - Quarterly Cash Flow Report
29/04/11	PRICE SENSITIVE	89.96KB	Share
ACR Appendix 3B
07/04/11		167.78KB	Share
ACR Axiron Launched by Eli Lilly in the United States
31/03/11	PRICE SENSITIVE	52.55KB	Share
ACR Acrux Declares First Dividend of 60 cents per share
24/03/11	PRICE SENSITIVE	46.13KB	Share
ACR Appendix 3B
16/03/11		167.39KB	Share
ACR Acrux Files Half Year Results
24/02/11		49.74KB	Share
ACR Half Year Accounts and Appendix 4D
24/02/11	PRICE SENSITIVE	272.94KB	Share
ACR Appendix 3B
15/02/11		167.41KB	Share
ACR Ceasing to be a substantial holder
04/02/11		60.33KB	Share
ACR Appendix 4C - Quarterly Cash Flow Report
31/01/11	PRICE SENSITIVE	89.75KB	Share
ACR Appendix 3B
21/01/11		167.41KB	Share
ACR Regulatory update on animal health product
13/01/11		20.07KB	Share
ACR Share Trading Policy
24/12/10		24.62KB	Share

REFRESH

First 4 5 6 7 8

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.8¢		Change 0.000(0.00%)		Mkt cap ! $7.366M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
5	883823	1.7¢

Sellers (Offers)

Price($)	Vol.	No.
1.8¢	503693	3

View Market Depth

No.	Vol.	Price($)
5	883823	0.017
10	962673	0.016
6	1361882	0.015
2	140000	0.014
3	486850	0.013

Price($)	Vol.	No.
0.018	503693	3
0.020	56617	4
0.021	111922	1
0.022	168642	2
0.023	381179	1

Last trade - 13.16pm 30/07/2025 (20 minute delay)

ACR (ASX) Chart

Day chart unavailable

ACRUX LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available